Advertisement

European Journal of Clinical Pharmacology

, Volume 70, Issue 7, pp 849–857 | Cite as

Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications

  • V. Abbing-Karahagopian
  • C. Huerta
  • P. C. Souverein
  • F. de Abajo
  • H. G. M. Leufkens
  • J. Slattery
  • Y. Alvarez
  • M. Miret
  • M. Gil
  • B. Oliva
  • U. Hesse
  • G. Requena
  • F. de Vries
  • M. Rottenkolber
  • S. Schmiedl
  • R. Reynolds
  • R. G. Schlienger
  • M. C. H. de Groot
  • O. H. Klungel
  • T. P. van Staa
  • L. van Dijk
  • A. C. G. Egberts
  • H. Gardarsdottir
  • M. L. De BruinEmail author
Pharmacoepidemiology and Prescription

Abstract

Purpose

Drug utilization studies have applied different methods to various data types to describe medication use, which hampers comparisons across populations. The aim of this study was to describe the time trends in antidepressant prescribing in the last decade and the variation in the prevalence, calculated in a uniform manner, in seven European electronic healthcare databases.

Methods

Annual prevalence per 10,000 person-years (PYs) was calculated for 2001–2009 in databases from Spain, Germany, Denmark, the United Kingdom (UK), and the Netherlands. Prevalence data were stratified according to age, sex, antidepressant type (selective serotonin re-uptake inhibitors [SSRIs] or tricyclic antidepressants [TCAs]) and major indications.

Results

The age- and sex-standardized prevalence was lowest in the two Dutch (391 and 429 users per 10,000 PYs) and highest in the two UK (913 and 936 users per 10,000 PYs) populations in 2008. The prevalence in the Danish, German, and Spanish populations was 637, 618, and 644 users per 10,000 PY respectively. Antidepressants were prescribed most often in 20- to 60-year-olds in the two UK populations compared with the others. SSRIs were prescribed more often than TCAs in all except the German population. In the majority of countries we observed an increasing trend of antidepressant prescribing over time. Two different methods identifying recorded indications yielded different ranges of proportions of patients recorded with the specific indication (15–57 % and 39–69 % for depression respectively).

Conclusion

Despite applying uniform methods, variations in the prevalence of antidepressant prescribing were obvious in the different populations. Database characteristics and clinical factors may both explain these variations.

Keywords

Antidepressants Selective serotonin reuptake inhibitors Tricyclic antidepressants Prevalence Electronic healthcare databases Standardization 

Notes

Acknowledgements

The research leading to these results was conducted as part of the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, www.imi-protect.eu), which is a public–private partnership coordinated by the European Medicines Agency. Roman Gerlach and Martin Tauscher from the KVB (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany) are acknowledged for their support in data acquisition.

Funding

The PROTECT project has received support from the Innovative Medicine Initiative (IMI) Joint Undertaking (www.imi.europa.eu) under Grant Agreement no. 115004, the resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and the kind contribution of the EFPIA companies. In the context of the IMI Joint Undertaking (IMI JU), the Department of Pharmacoepidemiology, Utrecht University, also received a direct financial contribution from Pfizer. The views expressed are those of the authors only and not of their respective institutions or companies.

The Division of Pharmacoepidemiology and Clinical Pharmacology has received unrestricted funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the Royal Dutch Pharmacists Association (KNMP), the privately/publically funded Top Institute Pharma (www.tipharma.nl), includes co-funding from universities, government, and industry), the EU Innovative Medicines Initiative (IMI), the EU 7th Framework Program (FP7), the Dutch Ministry of Health, and industry (including GlaxoSmithKline, Pfizer, and others).

Supplementary material

228_2014_1676_MOESM1_ESM.docx (11 kb)
ESM 1 (DOCX 11 kb)

References

  1. 1.
    Strom B (2005) Pharmacoepidemiology, 4th edn. Wiley, LondonGoogle Scholar
  2. 2.
    Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC (2007) Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 98(1–2):109–115PubMedCrossRefGoogle Scholar
  3. 3.
    Rosholm JU, Andersen M, Gram LF (2001) Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 56(12):923–929PubMedCrossRefGoogle Scholar
  4. 4.
    Development of Drug Utilization Indicators: A feasibility study using existing aggregated administrative databases 2002. Accessed December 2012. Available from: http://www.cihi.ca/CIHI-ext-portal/pdf/internet/PDF_INDI_DRUG_FINAL_REPORT_EN
  5. 5.
    Exeter D, Robinson E, Wheeler A (2009) Antidepressant dispensing trends in New Zealand between 2004 and 2007. Aust N Z J Psychiatry 43(12):1131–1140PubMedCrossRefGoogle Scholar
  6. 6.
    Aguglia E, Ravasio R, Simonetti M, Pecchioli S, Mazzoleni F (2012) Use and treatment modalities for SSRI and SNRI antidepressants in Italy during the period 2003–2009. Curr Med Res Opin 28(9):1475–1484PubMedCrossRefGoogle Scholar
  7. 7.
    Smith AJ, Tett SE (2009) How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003–6. Drugs Aging 26(2):113–122PubMedCrossRefGoogle Scholar
  8. 8.
    Patten SB, Wang JL, Williams JV, Lavorato DH, Beck CA, Bulloch AG (2010) Frequency of antidepressant use in relation to recent and past major depressive episodes. Can J Psychiatry 55(8):532–535PubMedGoogle Scholar
  9. 9.
    Sundell KA, Gissler M, Petzold M, Waern M (2011) Antidepressant utilization patterns and mortality in Swedish men and women aged 20–34 years. Eur J Clin Pharmacol 67(2):169–178PubMedCrossRefGoogle Scholar
  10. 10.
    Volkers AC, Heerdink ER, van Dijk L (2007) Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001–2005). Pharmacoepidemiol Drug Saf 16(9):1054–1062PubMedCrossRefGoogle Scholar
  11. 11.
    Athanasopoulos C, Pitychoutis PM, Messari I, Lionis C, Papadopoulou-Daifoti Z (2012) Is Drug Utilization in Greece Sex dependent? A Population-based Study. Basic Clin Pharmacol Toxicol 112(1):55–62PubMedCrossRefGoogle Scholar
  12. 12.
    Parabiaghi A, Franchi C, Tettamanti M, Barbato A, D’Avanzo B, Fortino I et al (2011) Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. Eur J Clin Pharmacol 67(10):1077–1083PubMedCrossRefGoogle Scholar
  13. 13.
    Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T (2009) Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 339:b3999PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Alonso MP, de Abajo FJ, Martinez JJ, Montero D, Martin-Serrano G, Madurga M (1997) [Evolution of antidepressive drug consumption in Spain. The impact of selective serotonin re-uptake inhibitors]. Med Clin (Barc) 108(5):161–166Google Scholar
  15. 15.
    Lidell E, Luepker R, Baigi A, Lagiou A, Hildingh C (2008) Medication usage among young adult women: a comparison between Sweden, the USA, and Greece. Nurs Health Sci 10(1):4–10PubMedCrossRefGoogle Scholar
  16. 16.
    Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Demyttenaere K et al (2008) Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 23(1):66–73PubMedCrossRefGoogle Scholar
  17. 17.
    Zito JM, Tobi H, de Jong-van den Berg LT, Fegert JM, Safer DJ, Janhsen K et al (2006) Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 15(11):793–798PubMedCrossRefGoogle Scholar
  18. 18.
    Bowers L, Callaghan P, Clark N, Evers C (2004) Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. Eur J Clin Pharmacol 60(1):29–35PubMedCrossRefGoogle Scholar
  19. 19.
    Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H et al (2004) Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:55–64PubMedGoogle Scholar
  20. 20.
    Abbing-Karahagopian V, Kurz X, de Vries F, van Staa TP, Alvarez Y, Hesse U et al (2014) Bridging differences in findings from observational pharmacoepidemiological studies: PROTECT project. Curr Clin Pharmacol 9(2):130–138PubMedCrossRefGoogle Scholar
  21. 21.
    Ohayon MM, Caulet M, Priest RG, Guilleminault C (1998) Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 51(3):273–283PubMedCrossRefGoogle Scholar
  22. 22.
    Pagura J, Katz LY, Mojtabai R, Druss BG, Cox B, Sareen J (2011) Antidepressant use in the absence of common mental disorders in the general population. J Clin Psychiatry 72(4):494–501PubMedCrossRefGoogle Scholar
  23. 23.
    Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D (2007) Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf 16(5):560–570PubMedCrossRefGoogle Scholar
  24. 24.
    Raymond CB, Morgan SG, Caetano PA (2007) Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv 58(1):79–84PubMedCrossRefGoogle Scholar
  25. 25.
    Sanyal C, Asbridge M, Kisely S, Sketris I, Andreou P (2011) The utilization of antidepressants and benzodiazepines among people with major depression in Canada. Can J Psychiatry 56(11):667–676PubMedGoogle Scholar
  26. 26.
    Sihvo S, Isometsa E, Kiviruusu O, Hamalainen J, Suvisaari J, Perala J et al (2008) Antidepressant utilisation patterns and determinants of short-term and non-psychiatric use in the Finnish general adult population. J Affect Disord 110(1–2):94–105PubMedCrossRefGoogle Scholar
  27. 27.
    Wittkampf LC, Smeets HM, Knol MJ, Geerlings MI, Braam AW, De Wit NJ (2010) Differences in psychotropic drug prescriptions among ethnic groups in the Netherlands. Soc Psychiatry Psychiatr Epidemiol 45(8):819–826PubMedCrossRefGoogle Scholar
  28. 28.
    Ubeda A, Cardo E, Selles N, Broseta R, Trillo JL, Fernandez-Llimos F (2007) Antidepressant utilization in primary care in a Spanish region: impact of generic and reference-based pricing policy (2000–2004). Soc Psychiatry Psychiatr Epidemiol 42(3):181–188PubMedCrossRefGoogle Scholar
  29. 29.
    Hansen DG, Sondergaard J, Vach W, Gram LF, Rosholm JU, Kragstrup J (2003) Antidepressant drug use in general practice: inter-practice variation and association with practice characteristics. Eur J Clin Pharmacol 59(2):143–149PubMedGoogle Scholar
  30. 30.
    Hansen DG, Rosholm JU, Gichangi A, Vach W (2007) Increased use of antidepressants at the end of life: population-based study among people aged 65 years and above. Age Ageing 36(4):449–454PubMedCrossRefGoogle Scholar
  31. 31.
    Hsia Y, Maclennan K (2009) Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK. Eur J Epidemiol 24(4):211–216PubMedCrossRefGoogle Scholar
  32. 32.
    Murray ML, de Vries CS, Wong IC (2004) A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 89(12):1098–1102PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Wijlaars LP, Nazareth I, Petersen I (2012) Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One 7(3):e33181PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Reseland S, Bray I, Gunnell D (2006) Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry 188:354–358PubMedCrossRefGoogle Scholar
  35. 35.
    Bramness JG, Walby FA, Tverdal A (2007) The sales of antidepressants and suicide rates in Norway and its counties 1980–2004. J Affect Disord 102(1–3):1–9PubMedCrossRefGoogle Scholar
  36. 36.
    Trifiro G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M et al (2007) Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004. Pharmacoepidemiol Drug Saf 16(5):552–559PubMedCrossRefGoogle Scholar
  37. 37.
    Fegert JM, Kolch M, Zito JM, Glaeske G, Janhsen K (2006) Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16(1–2):197–206PubMedCrossRefGoogle Scholar
  38. 38.
    Ufer M, Meyer SA, Junge O, Selke G, Volz HP, Hedderich J et al (2007) Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription-based analysis. Pharmacoepidemiol Drug Saf 16(10):1153–1160PubMedCrossRefGoogle Scholar
  39. 39.
    Hoffmann F, Glaeske G, Petermann F, Bachmann CJ (2012) Outpatient treatment in German adolescents with depression: an analysis of nationwide health insurance data. Pharmacoepidemiol Drug Saf 21(9):972–979PubMedCrossRefGoogle Scholar
  40. 40.
    Lapeyre-Mestre M, Desboeuf K, Aptel I, Chale JJ, Montastruc JL (1998) A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists. Clin Drug Investig 16(1):53–61PubMedCrossRefGoogle Scholar
  41. 41.
    Kjosavik SR, Hunskaar S, Aarsland D, Ruths S (2011) Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. Acta Psychiatr Scand 123(6):459–465PubMedCrossRefGoogle Scholar
  42. 42.
    Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Goldberg D, Magruder KM et al (1999) Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 60(Suppl 7):54–61PubMedGoogle Scholar
  43. 43.
    Roberts RE, Shema SJ, Kaplan GA, Strawbridge WJ (2000) Sleep complaints and depression in an aging cohort: a prospective perspective. Am J Psychiatry 157(1):81–88PubMedGoogle Scholar
  44. 44.
    Gardarsdottir H, Egberts AC, van Dijk L, Sturkenboom MC, Heerdink ER (2009) An algorithm to identify antidepressant users with a diagnosis of depression from prescription data. Pharmacoepidemiol Drug Saf 18(1):7–15PubMedCrossRefGoogle Scholar
  45. 45.
    Van Geffen EC, Gardarsdottir H, van Hulten R, van Dijk L, Egberts AC, Heerdink ER (2009) Initiation of antidepressant therapy: do patients follow the GP’s prescription? Br J Gen Pract 59(559):81–87PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • V. Abbing-Karahagopian
    • 1
  • C. Huerta
    • 2
  • P. C. Souverein
    • 1
  • F. de Abajo
    • 3
    • 4
  • H. G. M. Leufkens
    • 1
    • 5
  • J. Slattery
    • 6
  • Y. Alvarez
    • 6
  • M. Miret
    • 7
  • M. Gil
    • 2
  • B. Oliva
    • 2
  • U. Hesse
    • 8
  • G. Requena
    • 4
  • F. de Vries
    • 1
    • 9
  • M. Rottenkolber
    • 10
  • S. Schmiedl
    • 11
  • R. Reynolds
    • 12
  • R. G. Schlienger
    • 13
  • M. C. H. de Groot
    • 1
  • O. H. Klungel
    • 1
  • T. P. van Staa
    • 1
    • 14
  • L. van Dijk
    • 1
    • 15
  • A. C. G. Egberts
    • 1
    • 16
  • H. Gardarsdottir
    • 1
    • 16
  • M. L. De Bruin
    • 1
    • 5
    Email author
  1. 1.Division of Pharmacoepidemiology and Clinical PharmacologyUtrecht UniversityUtrechtThe Netherlands
  2. 2.BIFAP Research Unit, Division of Pharmacoepidemiology and PharmacovigilanceAgencia Espanola de Medicamentos y Productos Sanitarios (AEMPS)MadridSpain
  3. 3.Clinical Pharmacology UnitUniversity Hospital Príncipe de AsturiasMadridSpain
  4. 4.Department of Pharmacology, School of MedicineUniversity of AlcaláMadridSpain
  5. 5.MEB, Medicines Evaluation BoardUtrechtThe Netherlands
  6. 6.EMA, European Medicines AgencyLondonUK
  7. 7.Merck KGaAGenevaSwitzerland
  8. 8.National Institute for Health Data and Disease ControlCopenhagenDenmark
  9. 9.Department of Clinical Pharmacy and Toxicology University Medical Center Maastricht and School for Public Health and Primary care (CAPHRI)Maastricht UniversityMaastrichtThe Netherlands
  10. 10.Institute for Medical Information Sciences, Biometry and EpidemiologyLudwig-Maximilians-UniversitaetMunichGermany
  11. 11.Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Germany/Philipp Klee-Institute for Clinical PharmacologyHELIOS ClinicWuppertalGermany
  12. 12.PfizerNew YorkUSA
  13. 13.Global Clinical EpidemiologyNovartis Pharma AGBaselSwitzerland
  14. 14.CPRD, Clinical Practice Research DatalinkLondonUK
  15. 15.NIVEL, Netherlands Institute for Healthcare ResearchUtrechtThe Netherlands
  16. 16.UMCU, University Medical Center UtrechtUtrechtThe Netherlands

Personalised recommendations